Shenzhen Bioeasy Biotechnology Co Ltd
SZSE:300942
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shenzhen Bioeasy Biotechnology Co Ltd
Total Current Assets
Shenzhen Bioeasy Biotechnology Co Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shenzhen Bioeasy Biotechnology Co Ltd
SZSE:300942
|
Total Current Assets
¥751.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shanghai Conant Optical Co Ltd
HKEX:2276
|
Total Current Assets
¥1.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Total Current Assets
¥6.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Total Current Assets
¥8.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Total Current Assets
¥5.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
15%
|
CAGR 10-Years
27%
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Total Current Assets
¥25.6B
|
CAGR 3-Years
40%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Shenzhen Bioeasy Biotechnology Co Ltd
Glance View
Shenzhen Bioeasy Biotechnology Co., Ltd. engages in the research and development, production, and sale of food and drug safety and clinical diagnostic products. The company is headquartered in Shenzhen, Guangdong and currently employs 650 full-time employees. The company went IPO on 2021-02-09. The Company’s main products are food safety rapid testing reagents, rapid testing instruments, related testing services and in vitro diagnostic point-of-car testing (POCT) products, such as colloidal gold immunochromatographic test papers, enzyme-linked immunoassay (ELISA) kits, nucleic acids extraction kit, portable food rapid analysis system, infectious disease detection series and fluorescence immunoassay analyzer, etc. Its products are mainly used in dairy, meat, aquatic products, grains and oils, fruits and vegetables and other food fields that require rapid testing, as well as in the cultivation and breeding fields.
See Also
What is Shenzhen Bioeasy Biotechnology Co Ltd's Total Current Assets?
Total Current Assets
751.6m
CNY
Based on the financial report for Dec 31, 2024, Shenzhen Bioeasy Biotechnology Co Ltd's Total Current Assets amounts to 751.6m CNY.
What is Shenzhen Bioeasy Biotechnology Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
6%
Over the last year, the Total Current Assets growth was 2%. The average annual Total Current Assets growth rates for Shenzhen Bioeasy Biotechnology Co Ltd have been -6% over the past three years , 6% over the past five years .
